Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of rMenB+OMV NZ Meningococcal Group B Vaccine in Korean Adolescents
2014-005083-15Phase 3
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Multicomponent meningococcal B vaccine in meningococcal disease (2 arms), sponsored by Novartis. Primary endpoint: Primary immunogenicity endpoint.
02
Drugs
Multicomponent meningococcal B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2014-005083-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005083-15.